Bessler W G, Huber M, Baier W
Institut für Immunbiologie, Medizinische Fakultät der Universität, Freiburg, Germany.
Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):551-8. doi: 10.1016/s0192-0561(97)00055-6.
The bacterial extract Broncho-Vaxom used for the prevention and treatment of recurrent respiratory tract infections is an immunomodulator in vitro and in vivo, as determined in a murine model. The extract acts, on the one hand, as macrophage activator and polyclonal B-lymphocyte stimulant. On the other hand, after repeated intraperitoneal or oral immunizations, the extract is immunogenic, inducing serum IgG binding to the bacterial strains used for the preparation of the extract. On bacteria, the sera recognize the cell wall components porin, lipoprotein/lipopeptide and murein. The bacterial extract also exhibits adjuvant properties when applied in mixture with antigens, such as TNP-BSA or an influenza vaccine preparation. The unspecific and the immunospecific stimulatory effect of the extract as well as its adjuvant properties could be of importance for understanding its therapeutic effect.
用于预防和治疗复发性呼吸道感染的细菌提取物Broncho-Vaxom在体外和体内均具有免疫调节作用,这是在小鼠模型中确定的。一方面,该提取物可作为巨噬细胞激活剂和多克隆B淋巴细胞刺激剂。另一方面,经反复腹腔内或口服免疫后,该提取物具有免疫原性,可诱导血清IgG与用于制备提取物的细菌菌株结合。血清可识别细菌细胞壁成分孔蛋白、脂蛋白/脂肽和胞壁质。当与抗原(如TNP-BSA或流感疫苗制剂)混合使用时,该细菌提取物还具有佐剂特性。提取物的非特异性和免疫特异性刺激作用及其佐剂特性对于理解其治疗效果可能具有重要意义。